Healthcare services tied to reimbursement strategy now sit much closer to commercial success than many product teams once assumed. For pharmaceutical, medical device and diagnostic companies, clinical promise is not enough to carry a product into sustainable use. A therapy or procedure can clear regulatory review, show patient benefit and still face a weak launch if payers, providers and internal sales teams lack a clear path to reimbursement. The pressure is sharper for companies entering the U.S. market from systems where payment is more centralized or less dependent on a payer-by-payer strategy. The U.S. reimbursement environment rewards early planning, precise education and disciplined follow-through.
Thank you for Subscribing to Healthcare Business Review Weekly Brief
